Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - ROCKET PHARMACEUTICALS, INC. | itek-ex321_6.htm |
| EX-31.2 - EX-31.2 - ROCKET PHARMACEUTICALS, INC. | itek-ex312_7.htm |
| EX-31.1 - EX-31.1 - ROCKET PHARMACEUTICALS, INC. | itek-ex311_8.htm |
| EX-21.1 - EX-21.1 - ROCKET PHARMACEUTICALS, INC. | itek-ex211_1186.htm |
| 10-K - 10-K - ROCKET PHARMACEUTICALS, INC. | itek-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Forms S-8 (Nos. 333-204501 and 333-212308) and on Form S-3 (No. 333-210585) of Inotek Pharmaceuticals Corporation of our report dated March 16, 2017, relating to the consolidated financial statements of Inotek Pharmaceuticals Corporation, appearing in this Annual Report on Form 10-K of Inotek Pharmaceuticals Corporation for the year ended December 31, 2016.
|
/s/ RSM US LLP |
|
|
|
|
|
Boston, Massachusetts |
|
March 16, 2017 |